Cinnabloc

Cinnabloc

cinnarizine

Manufacturer:

Lloyd

Distributor:

Aldril
Full Prescribing Info
Contents
Cinnarizine.
Description
Each tablet contains: Cinnarizine 25 mg.
Each capsule contains: Cinnarizine 75 mg.
Action
Pharmacology: Pharmacokinetics: Cinnarizine is absorbed from the gastrointestinal tract, peak plasma concentrations occurring 2 to 4 hours after oral administration. It undergoes metabolism and has half-life of 3 to 6 hours. Cinnarizine is excreted in the feces mainly as unchanged drug, and in the urine predominantly as metabolites.
Indications/Uses
For the symptomatic treatment of nausea and vertigo caused by Meniere's disease and other vestibular disorder and for the prevention and treatment of motion sickness; also used in the management of peripheral and cerebral vascular disorder.
Dosage/Direction for Use
Cerebral circulation disorder: 25 mg: 1-2 tablets three times a day.
75 mg: 1 capsule daily.
Peripheral circulation disorders: 25 mg: 1-3 tablets three times a day.
75 mg: 1 capsule daily.
Vestibular disturbances: 25 mg: 1 tablet three times daily.
75 mg: 1 capsule daily.
Motion sickness: 25 mg: 1 tablet or ½ before traveling repeated every 6 hours.
75 mg: 1 capsule daily maximum dosage should not exceed 225 mg (3 capsules) daily.
It should be taken with food or as prescribed by the physician.
Special Precautions
Should not be given to premature infants or neonates, this group of patients has an increased susceptibility to antimuscarinic effects.
Adverse Reactions
In severe over dosage with antihistamines the stomach should be emptied. Emetics may be tried if the patient is alert and there are no symptoms of toxicity but may be ineffective due to the antiemetic activity of the antihistamine. Activated charcoal this been given as saline laxatives especially if sustained-release preparations were involved. Convulsions may be controlled with diazepam, although it has been suggested that CNS depressants should be avoided. Central stimulants may increase the risk convulsions and their avoidance is advisable.
Drug Interactions
Sedating antihistamines may enhance the sedative effects of CNS depressants including alcohol, barbiturates, hypnotics, opioid analgesic, anxiolytic sedatives, and antipsychotics. Sedative interactions apply to a lesser extent with the non-sedative antihistamines, they do not appear to potentiate the effects of alcohol but should be avoided in excess.
Sedating antihistamines have an additive antimuscarinic action with other antimuscarinic drugs such as atropine and some antidepressant. Potentially hazardous ventricular arrhythmias have occurred when the non-sedating antihistamines astemizole and terfenadine have been given concomitantly with drug liable to interfere with their hepatic metabolism, with other potentially arrhythmogenic drugs including those that prolong the QT interval, or with those likely to cause electrolyte imbalance. For full details see under Astemizole.
It has been suggested that some sedating antihistamines could mask the warning signs of damage caused by ototoxic drugs such as aminoglycoside antibiotics.
Antihistamines may suppress the cutaneous histamine response to allergen extracts and should be stopped several days before skin testing.
Storage
Store at temperatures not exceeding 30°C.
MIMS Class
Antivertigo Drugs / Peripheral Vasodilators & Cerebral Activators
ATC Classification
N07CA02 - cinnarizine ; Belongs to the class of antivertigo preparations.
Presentation/Packing
Cap 75 mg x 10's. Tab 25 mg x 100's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in